Review on Medical Applications of Manganese Oxide (Mn²⁺, Mn³⁺, and Mn⁴⁺) Magnetic Nanoparticles

Table 3

Manganese oxides-based drug delivery carrier.

S. no.	Nanoformulation	Preparation method	Size (nm)	PDI (mV)	Zeta potential (mV)	Drug	Drug-loading efficiency (%)	Drug encapsulation efficiency (%)	Drug release (%)	Disease	References
1	Polydopamine–manganese dioxide-IR780 iodide	Self-polymerization	244.6	0.172	−19.5 ± 1	Polydopamine	97.5	9.18	—	—	[155]
2	Hollow MnO2	Reduction	—	—	—	Doxorubicin	20.0	50.2	38.7	HeLa, MCF-7	[178]
3	MnO2-DOX-C6	Reduction	55.34 ± 2.93	0.212	27.30 ± 2.11	Doxorubicin	—	—	66.84 ± 3.8	—	[179]
4	DOX/MnO2@ZIF-8^c	—	206.22 ± 21.00 nm	—	—	Doxorubicin	12	—	82	Lung cancer	[181]
5	Biotin–PEG Mn3O4 nanocuboids	—	—	—	—	Gemcitabine	—	—	—	Breast cancer	[184]
6	Mno2 dopped triple hybrid mesoporous organosilica nanoparticles	Sol–gel method	271	—	−6.98	Doxorubicin	—	13.5	—	Breast cancer	[187]
7	DUCNP@Mn−MOF/FOE	—	—	—	—	3-F-10-OH-Evodiamine	83	—	—	—	[188]
8	ST-SA@MNCs^b	Chemical precipitation	21 nm	—	−15	Doxorubicin hydrochloride	—	—	81.4 ± 1.6	HePG2	[109]
9	DOX@(hPDA/MnO2)-PEG	—	23.6	—	−22.6	Doxorubicin	—	—	43	—	[190]
10	Hollow MnO2	—	100	—	−22	Doxorubicin	94.67	—	—	—	[191]
11	tLyP-1-CD-DOPA-MnO2@PTX^a	137.0 ± 1.9	—	16.0 ± 1.3	—	Paclitaxel	—	—	—	Orthotopic glioma	[192]
12	Aptamer mediated hollow MnO2	100 ± 10	—	33.84–36.06	—	Sorafenib	22	88	18	Liver cancer	[193]
13	Mn3O4@PAA@ZIF-8/MTX	Hydrothermal	—	—	—	Methotrexate	80	—	53	BT-474 and MCF-7	[194]
14	AuNPs@MnCO3/Mn3O4	—	—	—	—	Doxorubicin and propium iodide	—	—	—	Breast cancer	[195]
15	Hollow MnO2	—	129 nm	—	−27	Bufalin	28.6 ± 3.5	80.0 ± 4.3	81 ± 2	H22	[196]
16	Au/MnO2	—	146 nm	—	+13.6	Doxorubicin	99.1	—	25	—	[197]

^atLyP-1-CD-DOPA-MnO₂@PTX, tLyP-1-modified dopamine (DOPA), β-cyclodextrin (CD)-coated paclitaxel (PTX), and manganese dioxide (MnO₂)-loaded nanoparticles. ^bST-SA@MNCs—serotonin–stearic acid-based bioconjugate modified manganese oxide-based nanocuboids. ^cDOX/MnO₂@ZIF-8—doxorubicin-loaded MnO₂@Zeolitic Imidazolate Framework-8.